The award win recognizes Nanoform as a listed company that places innovation at the center of its strategy for business development and introduces an innovative technology to the market.
Nanoform, an innovative nanoparticle medicine enabling company, today announced it has received ISO/IEC 27001:2013 certification for its Information Security Management System (ISMS).
Integrating bioanalysis with clinical studies and pharmacokinetics: an interview with Stuart McDougall
In this interview Stuart McDougall, Head of Bioanalytical Services at Arcinova (Northumberland, UK), discusses the technologies used to generate fast, reliable data for drug development and how recently Arcinova has been acquired by Quotient Sciences.
Technological advancements in all its glory, but we must never forget the importance of humanity in customer satisfaction
Sitting Down With… Peter Marks
Director of the Center for Biologics Evaluation and Research (CBER) at the FDA, USA
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.